Skip to main content

Table 1 Baseline characteristics of all patients

From: Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis

Ā 

All patients (nā€‰=ā€‰176)

EVO group (nā€‰=ā€‰90, 51.1%)

RTO group (nā€‰=ā€‰86, 48.9%)

P value

Age

60.3ā€‰Ā±ā€‰11.7

60.5ā€‰Ā±ā€‰11.9

59.5ā€‰Ā±ā€‰11.7

0.704

Male, n (%)

125 (71.0)

69 (76.7)

56 (65.1)

0.091

Etiology, n (%)

Ā Ā Ā 

0.395

Ā Hepatitis B virus

50 (28.4)

22 (24.4)

28 (32.6)

Ā 

Ā Hepatitis C virus

14 (8.0)

7 (7.8)

7 (8.1)

Ā 

Ā Alcohol

83 (47.2)

48 (53.3)

35 (40.7)

Ā 

Ā Other

29 (16.5)

13 (14.4)

16 (18.6)

Ā 

Diabetes, n (%)

50 (28.4)

24 (26.4)

26 (30.2)

0.298

Hepatocellular carcinoma, n (%)

50 (28.4)

24 (26.7)

26 (30.2)

0.600

Type of varices, n (%)

Ā Ā Ā 

0.470

Ā GOV2

99 (56.3)

53 (58.9)

46 (53.5)

Ā 

Ā IGV1

77 (43.7)

37 (41.1)

40 (46.5)

Ā 

Size of esophageal varices, n (%)

Ā Ā Ā 

0.244

Ā F0ā€“F1

102 (58.0)

47 (52.2)

55 (64.0)

Ā 

Ā F2ā€“F3

74 (42.0)

43 (47.8)

31 (36.0)

Ā 

Ā Hemoglobin, g/dL

9.0ā€‰Ā±ā€‰5.3

8.9ā€‰Ā±ā€‰2.2

9.1ā€‰Ā±ā€‰2.4

0.504

Ā Platelet count, Ɨ 109/L

103.1ā€‰Ā±ā€‰52.6

106.0ā€‰Ā±ā€‰45.5

100.4ā€‰Ā±ā€‰59.7

0.935

Ā INR

1.43ā€‰Ā±ā€‰0.32

1.44ā€‰Ā±ā€‰0.36

1.41ā€‰Ā±ā€‰0.71

0.362

Ā Alanine aminotransferase, IU/L

38.5ā€‰Ā±ā€‰49.7

42.1ā€‰Ā±ā€‰60.9

35.1ā€‰Ā±ā€‰34.5

0.418

Ā Total bilirubin, mg/dL

2.1ā€‰Ā±ā€‰3.2

2.3ā€‰Ā±ā€‰3.7

1.8ā€‰Ā±ā€‰2.5

0.154

Ā Serum albumin, g/dL

2.9ā€‰Ā±ā€‰0.2

2.9ā€‰Ā±ā€‰0.5

3.0ā€‰Ā±ā€‰0.5

0.274

Ā MELD score

12.6ā€‰Ā±ā€‰4.7

13.5ā€‰Ā±ā€‰4.5

11.7ā€‰Ā±ā€‰4.8

0.016

Ā Beta-blockers, n (%)

52 (29.5)

11 (12.2)

41 (47.7)

<ā€‰0.001

  1. Variables are expressed as meanā€‰Ā±ā€‰standard deviation or n (%)
  2. EVO endoscopic variceal obturation, RTO retrograde transvenous obliteration, GOV2 gastroesophageal varices type 2, IGV1 isolated gastric varices type 1, INR international normalized ratio, MELD, model for end-stage liver disease